The newest national review of Malaysia’s HIV response reads as both a progress report and a call to action. The Global AIDS Monitoring Report 2025, prepared by the HIV/STI/Hepatitis C Sector of the Disease Control Division at the Ministry of Health Malaysia, lays out gains, setbacks and the path ahead.

It is part audit, part strategy document. It sets out what is working and where fresh energy must be deployed if the country is to end AIDS as a public-health threat by 2030.

By the end of 2024 an estimated 83,937 people were living with HIV in Malaysia. Around two thirds of them — approximately 53,996 people — were aware of their status and recorded in the national surveillance system.

Of those diagnosed, treatment coverage was encouraging: 94% were reported to be receiving antiretroviral therapy by December 2024. Those figures show clear success in linking diagnosed individuals to care.

“This commitment must extend to marginalised and criminalised groups. Legal barriers, stigma and discrimination undermine access. Policy measures on privacy, non-discrimination and harm reduction must move from paper to practice to ensure equitable access.”

They also reveal a stubborn gap: nearly one third of people with HIV remain undiagnosed, outside the health system and at risk of onward transmission.

The shape of the epidemic has shifted. Where injecting drug use once dominated transmission, sexual transmission now accounts for most new infections. Risk concentrates among specific groups: men who have sex with men, transgender women and women at risk carry a disproportionate burden.

The report stresses the need for responses that are tailored to behaviour, social context and lived experience rather than generic programmes.

Diagnosis is pivotal. Without it, treatment cannot begin and viral suppression cannot be achieved. Viral suppression matters not only for the person on treatment but for public-health prevention: sustained suppression effectively prevents sexual transmission.

The report highlights expanded testing options. Digital tools and self-testing initiatives aim to reach people who face stigma or logistical barriers to clinic access. These innovations reduce friction and can link individuals to counselling, confirmatory testing and rapid treatment starts.

Yet technology alone will not reach everyone; social, legal and economic barriers persist.

Prevention efforts are increasingly targeted. Outreach, peer-led interventions, online campaigns and distribution of prevention commodities are prominent. Prevention packages are designed for different groups.

Biomedical tools such as pre-exposure prophylaxis offer powerful protection, but wider and more equitable access remains a priority. Harm-reduction approaches are evolving too. Opioid substitution therapy is replacing needle-syringe exchange in several settings, offering a dual benefit: reducing injecting-related transmission while supporting people who use drugs to stabilise and access care.

Coinfections complicate care. Tuberculosis, viral hepatitis and sexually transmitted infections commonly occur in people living with HIV. Integrated care models — combining screening, prevention and treatment for TB and viral hepatitis into HIV services — are essential to reduce morbidity and mortality. Tuberculosis preventive therapy and hepatitis B and C screening are cited as core parts of this integrated approach.

Malaysia frames its HIV response within the broader promise of universal health coverage. The objective is clear: prevention, testing, treatment and care should be accessible to everyone without financial hardship.

“Reducing stigma, encouraging diagnosis with compassion, and ensuring supportive care will widen reach among key populations. Stigma undermines testing and treatment uptake. Fear of judgement, discrimination or legal consequences keeps people away.”

This commitment must extend to marginalised and criminalised groups. Legal barriers, stigma and discrimination undermine access. Policy measures on privacy, non-discrimination and harm reduction must move from paper to practice to ensure equitable access.

The report signals worrying trends. After a period of sharp reductions in new infections, progress has slowed since about 2010. New infections and prevalence are rising in key populations.

That trend threatens national targets. To meet the 2030 goals — commonly summarised as 95% diagnosed, 95% of those on treatment, and 95% virally suppressed — Malaysia must find undiagnosed people, rapidly link them to care, and support sustained adherence.

Operational priorities are tangible. Case finding needs innovation. Community-based testing, partner notification, self-testing with supportive follow-up, and mobile outreach can reach people who avoid traditional services.

Linkage to care must be immediate and seamless. Delays between diagnosis and therapy reduce the chance of achieving viral suppression and increase transmission risk.

Treatment continuity, retention in care, adherence support and simplified regimens will make a difference. Prevention packages must be comprehensive, combining condoms, education, PrEP, harm reduction and gender-affirming care where needed.

Community engagement is critical. Grassroots organisations bring trust, cultural competence and reach. They often operate on limited funds in difficult legal environments. Strengthening and sustainably funding community-led services is pragmatic. Where formal health systems struggle to reach people, community networks succeed. Investing in them saves lives and resources.

Data quality is improving but gaps remain. Surveillance captures people who access services; hidden populations evade routine measurement. Better population estimates, expanded sentinel surveillance and routine monitoring of viral suppression will enable more responsive programming. High-quality data drives targeted resource allocation and accountability.

Policy coherence matters. Health policy aligned with social and legal reforms amplifies impact. Decriminalisation of behaviours that deter service use, robust anti-discrimination protections and enabling laws for harm reduction and community-led services all create an environment where prevention and care can flourish. Punitive approaches have the opposite effect, driving people away from health services.

Finance underpins every intervention. Sustained and predictable funding for prevention, diagnostics, treatment and community services is essential. Domestic financing, external support and innovative funding mechanisms must converge to maintain service continuity and expand reach. Investing in prevention reduces long-term treatment costs. The economic case for action is strong.

Crucially, the report emphasises the social determinants of health. Reducing stigma, encouraging diagnosis with compassion, and ensuring supportive care will widen reach among key populations. Stigma undermines testing and treatment uptake. Fear of judgement, discrimination or legal consequences keeps people away.

Compassionate health services change that. When clinics, outreach workers and counsellors offer non-judgemental care, more individuals will come forward for testing. When health staff and policies protect privacy and dignity, diagnosis becomes a safer step. That in turn improves linkage to treatment and retention in care.

Small operational shifts can change outcomes. Train health workers in respectful, non-stigmatising practice. Promote messaging that frames testing as routine, responsible and confidential. Support peer navigators who share lived experience. Fund community-led testing and counselling. Ensure legal protections for people seeking services. Combine these actions with expanded PrEP, harm reduction and digital self-testing to reach those who now remain hidden. Together, they make services more acceptable. They broaden uptake. They bring diagnosis and care closer to the people who need them most.

The report concludes with clear recommendations: scale up testing beyond traditional settings; expand self-testing with robust linkage mechanisms; make PrEP widely accessible; strengthen harm reduction; integrate HIV services with TB and viral hepatitis care; sustain funding for community-led responses; reform laws that hinder access; and improve surveillance.

Each recommendation is a component of a comprehensive strategy to reduce new infections, prevent illness and save lives.

Malaysia has the tools. Antiretroviral therapy, prevention medicines, effective diagnostics and integrated care models exist.

What remains is implementation at scale, equitable access and political will. The clock to 2030 is ticking. Actions taken now will determine whether the nation meets its targets.

Compassionate, stigma-free diagnosis and care will be decisive. They are the bridge between technical possibility and public-health reality.